Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk

Journal of the American College of Cardiology

Volumn 43, Issue 4, 2004, Pages 519-525

  Howard, Patricia A ^a   Delafontaine, Patrice ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Celecoxib Long term Arthritis Safety study; Coronary heart disease; Cyclooxygenase; Myocardial infarction; Nonaspirin nonsteroidal anti inflammatory drugs; Nonsteroidal anti inflammatory drugs; Vioxx Gastrointestinal Outcomes Research study

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; ISOENZYME; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ANIMAL; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COMBINATION; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; OSTEOARTHRITIS; PHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT;

EID: 1242340306     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.09.043     Document Type: Review

References (43)

1. Sanmuganathan P.S., Ghahramani P., Jackson P.R., et al. Aspirin for primary prevention of coronary heart disease Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials . Heart. 85:2001;265-271.
2. Aspirin for the primary prevention of cardiovascular events Recommendations and rationale . Ann Intern Med. 136:2002;157-160.
3. Collaborative overview of randomized trials of antiplatelet therapy-I Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients . BMJ. 308:1994;81-106.
4. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34;890-911.
5. Brooks P.M., Day R.O. Nonsteroidal anti-inflammatory drugs - differences and similarities. N Engl J Med. 324:1991;1716-1725.
6. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959.
7. IMS reports 16.9% growth in 2001 U.S. prescription sales. Westport, CT: IMS Health Inc., April 26, 2002. Available at: http://www.imshealth.com/public/ structure/dispcontent/1,2779,1203- 1203-144055,00.html. Accessibility verified December 16, 2002.
8. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 345:2001;1809-1817.
9. Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 104 Suppl:(3A):1998;2S-8S.
10. Rodriguez L.A. The effect of NSAIDs on the risk of coronary heart disease Fusion of clinical pharmacology and pharmacoepidemiologic data . Clin Exp Rheumatol. 19:(Suppl 25):2001;S41-S44.
11. Cryer B., Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 104:1998;413-421.
12. Whittle B.J.R., Higgs G.A., Eakins K.E., et al. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature. 284:1980;271-273.
13. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 88:2001;230-235.
14. Reilly I.A., Fitzgerald G.A. Inhibition of thromboxane formation in vivo and ex vivo Implications for therapy with platelet inhibitory drugs . Blood. 69:1987;180-186.
15. Patrono C., Ciabattoni G., Patrignani P., et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 72:1985;1177-1184.
16. Fitzgerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 345:2001;433-442.
17. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528.
18. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis The class study: a randomized controlled trial . JAMA. 284:2000;1247-1255.
19. MacDonald T.M., Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 361:2003;573-574.
20. Matsumoto A.K., Melian A., Mandel D.R., et al. A randomized controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 29:2002;1623-1630.
21. Reicin A.S., Shapiro D., Sperling R.S., et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflamamtory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 89:2002;204-209.
22. Konstam M.A., Weir M.R., Reicin A., et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 104:2001;2280-2288.
23. White W.B., Faich G., Whelton A., et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor versus ibuprofen or diclofenac. Am J Cardiol. 89:2002;425-430.
24. Mamdani M., Rochon P., Juurlink D.N., et al. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 163:2003;481-486.
25. Solomon D.H., Glynn R.J., Levin R., Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 162:2002;1099-1104.
26. Watson D.J., Rhodes T., Cai B., Guess H.A. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 162:2002;1105-1110.
27. Rahme E., Pilote L., LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 162:2002;1111-1115.
28. Ray W.A., Stein C.M., Hall K., et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease An observational cohort study . Lancet. 359:2002;118-123.
29. Ko D, Wang Y, Berger AK, et al. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am Heart J 2002;143:475-81.
30. Fitzgerald G.A., Austin Y.C.S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol. 19:(Suppl 25):2001;S31-S36.
31. Topper J.N., Cai J., Falb D., Gimbrone M.A. Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli Cyclooxygenase-2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress . Proc Natl Acad Sci USA. 93:1996;10417-10422.
32. Shinmura K., Tang X.L., Wang Y., et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA. 97:2000;10197-10202.
33. Bolli R., Shinmura K., Tang X.L., et al. Discovery of a new function of cyclooxygenase (COX)-2 Cox-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning . Cardiovasc Res. 55:2002;506-519.
34. Hennan J.K., Huang J., Barrett T.D., et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 104:2001;820-825.
35. Dowd N.P., Scully M., Adderley S.R., Cunningham A.J., Fitzgerald D.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 108:2001;585-590.
36. 2. Science. 296:2002;539-541.
37. DeMaria A.N. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol. 89:(Suppl):2002;33D-38D.
38. Lipani J. The data are inconclusive and these drugs are needed. Cleve Clin J Med. 68:2001;961-962.
39. Abramson S.B., Furst D.E., Hochberg M.C., Patrono C. Controversies in COX-2 inhibitor therapy Closing remarks . Clin Exp Rheumatol. 19:(Suppl 25):2001;S77-S80.
40. VanHecken A., Schwartz J.I., Depre M., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 40:2000;1109-1120.
41. Dalen J.E. Selective COX-2 inhibitors, NSAIDs, aspirin and myocardial infarction. Arch Intern Med. 162:2002;1091-1092.
42. Chenevard R., Hurlimann D., Bechir M., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 107:2003;405-409.
43. Altman R., Luciardi H.L., Muntaner J., et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (nut-2) pilot study . Circulation. 106:2002;191-195.